Correction

Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease (gfx350, 2018)

Journal

NEPHROLOGY DIALYSIS TRANSPLANTATION
Volume 33, Issue 7, Pages 1280-1280

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/ndt/gfy135

Keywords

-

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Recommended

No Data Available
No Data Available